Selank

Selank | Peptide Complex

Nootropic

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. It is an analogue of the endogenous tetrapeptide tuftsin, extended with a proline-glycine-proline sequence to improve stability and CNS penetration. Selank has been approved as a nootropic and anxiolytic drug in Russia and has undergone extensive preclinical and clinical research for anxiety, cognitive enhancement, and immune modulation — with a notable absence of sedation or dependence in research models.

• Anxiolytic Activity — Selank has demonstrated robust anxiolytic effects in both animal models and human clinical studies, reducing generalized anxiety without the sedation, tolerance, or dependency risks associated with benzodiazepines.

• Cognitive Enhancement — Research indicates Selank enhances memory consolidation, attention, and learning performance, potentially through BDNF upregulation and modulation of serotonin and dopamine neurotransmission.

• BDNF Upregulation — Studies have shown Selank increases brain-derived neurotrophic factor (BDNF) expression in the hippocampus, supporting neuroplasticity and long-term potentiation in cognitive research models.

• Immune Modulation — As a tuftsin analogue, Selank retains immunomodulatory properties, influencing IL-6, IL-1β, and interferon pathways and supporting adaptive immune function.

• Stress Resilience — Selank research has shown it may normalize stress-induced dysregulation of enkephalin metabolism and monoamine systems, supporting a balanced stress response without blunting alertness.